中和单克隆抗体预防COVID-19门诊患者住院与死亡的真实世界证据
mAb治疗与28天全因住院(4.0% vs 7.7%;调整OR 0.48;95%CI 0.38-0.60)和全因死亡(0.1% vs 0.9%;调整OR 0.11;95%CI 0.03-0.29)降低相关,差异持续至90天。
要点
- mAb治疗与COVID-19门诊患者28天住院和死亡风险降低强相关。
- 住院患者中mAb治疗者住院时间更短、机械通气风险更低。
- 基线住院风险越高亚组NNT越低,多合并症者NNT=17,未完全接种者NNT=24。
核心结论
- 真实世界数据显示,COVID-19门诊患者接受mAb治疗与住院和死亡减少强相关,且跨疫情阶段一致。
研究设计与样本
- 采用倾向匹配,每例接受mAb治疗者匹配约2.5例未接受mAb治疗者;36,077例感染者中2,675例接受mAb者匹配6,677例未接受者。
主要发现
- mAb治疗组对比未治疗组28天全因住院率为4.0% vs 7.7%(调整OR 0.48;95%CI 0.38-0.60)。
- mAb治疗组对比未治疗组28天全因死亡率为0.1% vs 0.9%(调整OR 0.11;95%CI 0.03-0.29),差异持续至90天。
- 住院患者中mAb治疗组住院时间5.8天 vs 8.5天,机械通气风险4.6% vs 16.6%。
- Delta变异株阶段预防住院的调整OR为0.35(95%CI 0.25-0.50),各亚组结果相似。
- 预防住院的NNT在基线住院风险较高亚组更低:多合并症NNT=17、未完全接种NNT=24,无合并症NNT=88、完全接种NNT=81。
临床怎么用
- 真实世界证据可支持mAb在COVID-19门诊患者中的实践与政策决策,包括稀缺资源分配。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neutralizing monoclonal antibodies (mAbs) were authorized for the treatment of COVID-19 outpatients based on clinical trials completed early in the pandemic, which were underpowered for mortality and subgroup analyses. Real-world data studies are promising for further assessing rapidly deployed therapeutics. RESEARCH QUESTION: Did mAb treatment prevent progression to severe disease and death across pandemic phases and based on risk factors, including prior vaccination status? STUDY DESIGN AND METHODS: This observational cohort study included nonhospitalized adult patients with SARS-CoV-2 infection from November 2020 to October 2021 using electronic health records from a statewide health system plus state-level vaccine and mortality data. Using propensity matching, we selected approximately 2.5 patients not receiving mAbs for each patient who received mAb treatment under emergency use authorization. The primary outcome was 28-day hospitalization; secondary outcomes included mortality and hospitalization severity. RESULTS: Of 36,077 patients with SARS-CoV-2 infection, 2,675 receiving mAbs were matched to 6,677 patients not receiving mAbs. Compared with mAb-untreated patients, mAb-treated patients had lower all-cause hospitalization (4.0% vs 7.7%; adjusted OR, 0.48; 95% CI, 0.38-0.60) and all-cause mortality (0.1% vs 0.9%; adjusted OR, 0.11; 95% CI, 0.03-0.29) to day 28; differences persisted to day 90. Among hospitalized patients, mAb-treated patients had shorter hospital length of stay (5.8 vs 8.5 days) and lower risk of mechanical ventilation (4.6% vs 16.6%). Results were similar for preventing hospitalizations during the Delta variant phase (adjusted OR, 0.35; 95% CI, 0.25-0.50) and across subgroups. Number-needed-to-treat (NNT) to prevent hospitalization was lower for subgroups with higher baseline risk of hospitalization; for example, multiple comorbidities (NNT = 17) and not fully vaccinated (NNT = 24) vs no comorbidities (NNT = 88) and fully vaccinated (NNT = 81). INTERPRETATION: Real-world data revealed a strong association between receipt of mAbs and reduced hospitalization and deaths among COVID-19 outpatients across pandemic phases. Real-world data studies should be used to guide practice and policy decisions, including allocation of scarce resources.
引用
- Wynia MK, Beaty LE, Bennett TD, et al. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Chest. 2022. PMID: 36441040. doi:10.1016/j.chest.2022.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。